Edition:
United Kingdom

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

14.20CNY
11 Dec 2017
Change (% chg)

¥0.68 (+5.03%)
Prev Close
¥13.52
Open
¥13.52
Day's High
¥14.30
Day's Low
¥13.52
Volume
12,094,990
Avg. Vol
7,650,497
52-wk High
¥16.70
52-wk Low
¥10.24

Latest Key Developments (Source: Significant Developments)

Zhejiang Hisun Pharmaceutical passes FDA approval
Tuesday, 21 Nov 2017 

Nov 21(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it received approval for a kind of tablet from U.S Food and Drug Administration .  Full Article

Zhejiang Hisun Pharmaceutical unit says product gets FDA approval
Monday, 20 Nov 2017 

Nov 20(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says co's Hangzhou-based unit's product simvastatin tablets, gets approval from U.S. Food and Drug Administration.  Full Article

Zhejiang Hisun Pharmaceutical says product gets FDA approval
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::Says its product, mycophenolate mofetil capsules, gets approval from U.S. Food and Drug Administration .  Full Article

Zhejiang Hisun Pharmaceutical says change of CFO
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::Says it appoints Liu Yuanyan as new CFO, replacing Guan Xuhua who resigns from the position due to internal change in job role.  Full Article

Zhejiang Hisun Pharmaceutical receives TGA-GMP certificate
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it received goods manufacture practice (GMP) certificate from Therapeutic Goods Administration .Certificate issued to crude drugs manufactured by the company and the valid period is until Nov. 26, 2020 .  Full Article

Zhejiang Hisun Pharmaceutical to invest 5.1 mln yuan to set up investment management JV
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:* Says it will invest 5.1 million yuan to set up Zhejiang-based investment management JV, which will be engaged in operation of pharmaceutical industry innovation projects, and hold 51 percent stake in JV after transaction .  Full Article

Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy
Tuesday, 9 Aug 2016 

Celsion Corp : Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy . Hisun will collaborate with Celsion around regulatory approval activities for GEN-1 with CFDA . Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with company's current suppliers .Will provide Hisun a percentage certain of China's commercial unit demand, and separately of global commercial unit demand.  Full Article

Zhejiang Hisun Pharmaceutical unit gets GMP certificate
Monday, 25 Jul 2016 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>: Says its unit receives goods manufacture practice (GMP) certificate .Says certificate issued to the unit's imported drug packing production line and the valid period is until July 3, 2021.  Full Article

Zhejiang Hisun Pharmaceutical signs $3 mln technology transfer agreement with Nascent
Tuesday, 19 Jul 2016 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>:Says it signs $3 million technology transfer agreement with Nascent Biotech, Inc, to get exclusive right for Pritumumab, a targeted therapy for epithelioma.  Full Article

Zhejiang Hisun Pharmaceutical unit passes FDA approval
Monday, 27 Jun 2016 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>: Says its unit receives ANDA approval for its irbesartan tablets from U.S Food and Drug Administration .Says company's unit will be able to sell its irbesartan tablets in the United States after receiving the FDA approval.  Full Article

Shanghai stocks end firmer, aided by surging property shares

SHANGHAI, Nov 29 Shanghai stocks reversed early losses to end firmer on Wednesday, bolstered by a surge in property shares and resources firms. ** At the close, the Shanghai Composite index was up 4.35 points or 0.13 percent at 3,338.00. ** The blue-chip CSI300 index was down 0.05 percent, with its financial sector sub-index higher by 0.77 percent, the consumer staples sector down 2.39 percent, the real estate index up 6.96 percent and healthcare sub-index down 1.49 percent. ** The